Cargando…

The effects of immune checkpoint modulators on the clinical course of patients with resectable hepatocellular carcinoma

BACKGROUND/AIM: Immune checkpoint proteins regulating T-cell mediated anti-tumor immunity have been reported to affect clinical outcomes in multiple malignancies. This study aimed to investigate the prognostic effect of histological expression of immune checkpoint proteins in patients with resected...

Descripción completa

Detalles Bibliográficos
Autores principales:	An, Jihyun, Kang, Hyo Jeong, Yu, Eunsil, Lee, Han Chu, Shim, Ju Hyun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Liver Cancer Association 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10035709/ https://www.ncbi.nlm.nih.gov/pubmed/37383538 http://dx.doi.org/10.17998/jlc.2022.03.06

Ejemplares similares

Role of 15-hydroxyprostaglandin dehydrogenase down-regulation on the prognosis of hepatocellular carcinoma
por: Yang, Jee Eun, et al.
Publicado: (2014)

Comparison of surgical resection versus transarterial chemoembolization with additional radiation therapy in patients with hepatocellular carcinoma with portal vein invasion
por: Lee, Danbi, et al.
Publicado: (2018)

Hepatocellular Carcinoma Arising in a Huge Hepatocellular Adenoma with Bone Marrow Metaplasia
por: Kang, Hyo Jeong, et al.
Publicado: (2018)

The effectiveness of transarterial chemoembolization in recurrent hepatocellular-cholangiocarcinoma after resection
por: Na, Seong Kyun, et al.
Publicado: (2018)

Advances in immune checkpoint inhibitors for hepatocellular carcinoma
por: Han, Ji Won, et al.
Publicado: (2021)

Overexpression of C-reactive Protein as a Poor Prognostic Marker of Resectable Hepatocellular Carcinomas
por: Shin, Jin Ho, et al.
Publicado: (2015)

Hepatic Resection for Hepatocellular Carcinoma in the Era of Molecular-targeted Agents and Immune Checkpoint Inhibitors in Japan
por: Taketomi, Akinobu
Publicado: (2021)

Neoadjuvant Immune Checkpoint Inhibitors for Resectable Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis
por: Zhao, Mei, et al.
Publicado: (2023)

Clinical Trials of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma
por: Dyhl-Polk, Anne, et al.
Publicado: (2021)

A simple and clinically applicable model to predict liver-related morbidity after hepatic resection for hepatocellular carcinoma
por: Choi, Jonggi, et al.
Publicado: (2020)

Cure the Incurable? Recent Breakthroughs in Immune Checkpoint Blockade for Hepatocellular Carcinoma
por: Chu, Pei-Yi, et al.
Publicado: (2021)

Loco-regional therapies competing with radiofrequency ablation in potential indications for hepatocellular carcinoma: a network meta-analysis
por: Kim, Ha Il, et al.
Publicado: (2023)

Clinical features and outcomes of patients with hepatocellular carcinoma complicated with bile duct invasion
por: An, Jihyun, et al.
Publicado: (2017)

Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: An Overview
por: van Doorn, Diederick J., et al.
Publicado: (2020)

Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma
por: Abd El Aziz, Mohamed A., et al.
Publicado: (2020)

Immune checkpoint inhibitor therapy for hepatocellular carcinoma
por: Ramai, Daryl, et al.
Publicado: (2022)

The clinical behavior and survival of patients with hepatocellular carcinoma and a family history of the disease
por: An, Jihyun, et al.
Publicado: (2019)

Continued value of the serum alpha-fetoprotein test in surveilling at-risk populations for hepatocellular carcinoma
por: An, Jihyun, et al.
Publicado: (2020)

Ranking of transarterial and targeted therapies for advanced hepatocellular carcinoma in the era of immuno‐oncology: A network meta‐analysis of randomized sorafenib‐controlled trials
por: An, Jihyun, et al.
Publicado: (2022)

Multidisciplinary treatment with immune checkpoint inhibitors for advanced stage hepatocellular carcinoma
por: Lee, Ahlim, et al.
Publicado: (2022)

Association between statin use and the prognosis of hepatocellular carcinoma after resection: a nationwide cohort study
por: Jeon, Dongsub, et al.
Publicado: (2023)

Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Opportunities and Challenges
por: Liu, Xiufeng, et al.
Publicado: (2019)

Optimizing radiotherapy with immune checkpoint blockade in hepatocellular carcinoma
por: Choi, Changhoon, et al.
Publicado: (2019)

Adverse Effects of Immune-Checkpoint Inhibitors in Hepatocellular Carcinoma
por: Cui, Tian-ming, et al.
Publicado: (2020)

Emerging Role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma
por: Longo, Vito, et al.
Publicado: (2019)

Hepatocellular carcinoma and immunotherapy: Beyond immune checkpoint inhibitors
por: Abushukair, Hassan Mohammed, et al.
Publicado: (2022)

Advances in Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma
por: Chen, Yue, et al.
Publicado: (2022)

Clinical course and role of embolization in patients with spontaneous rupture of hepatocellular carcinoma
por: Park, Juil, et al.
Publicado: (2022)

Hepatocellular carcinoma immune prognosis score predicts the clinical outcomes of hepatocellular carcinoma patients receiving immune checkpoint inhibitors
por: Zhang, Rujia, et al.
Publicado: (2023)

Immune Checkpoint Blockade Therapy for Hepatocellular Carcinoma: Clinical Challenges and Considerations
por: Zhang, Qi, et al.
Publicado: (2020)

Clinical Outcomes in Fibrolamellar Hepatocellular Carcinoma Treated with Immune Checkpoint Inhibitors
por: Chen, Krista Y., et al.
Publicado: (2022)

Fibroblast growth factor receptor isotype expression and its association with overall survival in patients with hepatocellular carcinoma
por: Lee, Hyo Jeong, et al.
Publicado: (2015)

Immune Checkpoint Blockade in Chinese Patients With Hepatocellular Carcinoma: Characteristics and Particularity
por: Wu, Yaoqiang, et al.
Publicado: (2022)

Immune Phenotype and Immune Checkpoint Inhibitors for the Treatment of Human Hepatocellular Carcinoma
por: Nishida, Naoshi, et al.
Publicado: (2020)

Guanabenz Acetate Induces Endoplasmic Reticulum Stress–Related Cell Death in Hepatocellular Carcinoma Cells
por: Kang, Hyo Jeong, et al.
Publicado: (2019)

Immune Checkpoint FGL1 Expression of Circulating Tumor Cells Is Associated With Poor Survival in Curatively Resected Hepatocellular Carcinoma
por: Yan, Qing, et al.
Publicado: (2022)

Predictive Biomarkers for Immune-Checkpoint Inhibitor Treatment Response in Patients with Hepatocellular Carcinoma
por: Ji, Jun Ho, et al.
Publicado: (2023)

Response Prediction in Immune Checkpoint Inhibitor Immunotherapy for Advanced Hepatocellular Carcinoma
por: Hung, Hao-Chien, et al.
Publicado: (2021)

Immune checkpoint inhibition: prospects for prevention and therapy of hepatocellular carcinoma
por: Elsegood, Caryn L, et al.
Publicado: (2017)

Monitoring Immune Checkpoint Regulators as Predictive Biomarkers in Hepatocellular Carcinoma
por: Shrestha, Ritu, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_8aemtimj6a3pgaa8klt5m4opkd